Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis

Bioorg Med Chem Lett. 2022 Oct 1:73:128891. doi: 10.1016/j.bmcl.2022.128891. Epub 2022 Jul 13.


TYK2 is a member of the JAK family of kinases and a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Supported by compelling data from human genetic association studies, TYK2 inhibition is an attractive therapeutic strategy for these diseases. Herein, we report the discovery of a series of highly selective catalytic site TYK2 inhibitors designed using FEP+ and structurally enabled design starting from a virtual screen hit. We highlight the structure-based optimization to identify a lead candidate 30, a potent cellular TYK2 inhibitor with excellent selectivity, pharmacokinetic properties, and in vivo efficacy in a mouse psoriasis model.

Keywords: FEP; Psoriasis; Pyrrolidino-pyridine; Pyrrolidino-pyrimidine; TYK2 inhibitor.

MeSH terms

  • Animals
  • Humans
  • Janus Kinases
  • Mice
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Psoriasis* / drug therapy
  • Rodentia
  • TYK2 Kinase*


  • Protein Kinase Inhibitors
  • Janus Kinases
  • TYK2 Kinase
  • TYK2 protein, human